A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

December 15, 2016

Study Completion Date

December 15, 2016

Conditions
Parainfluenza
Interventions
DRUG

DAS181 dry powder, formulation F02

DRUG

Lactose Placebo

Trial Locations (45)

10021

Weill Cornell Medical College/New York Presbyterian Hospital, New York

10065

Weill Cornell Medical College-Peds, New York

10461

Montefiore Medical Center, The Bronx

14642

University of Rochester Medical Center, Rochester

15213

University of Pittsburgh Medical Center, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

Hospital of the University of Pennsylvania, Philadelphia

21287

John Hopkins University School of Medicine, Baltimore

23298

Virginia Commonwealth, Richmond

27710

Duke University Medical Center, Durham

29425

Medical University of South Carolina, Charleston

37232

Vanderbilt- Henry-Joyce Cancer Clinic, Nashville

38105

St. Jude Children's Research Hospital, Memphis

42367

Indiana Blood and Marrow Transplantation, Indianapolis

43205

Nationwide Children's, Columbus

44195

Cleveland Clinic, Cleveland

45229

Cincinnati Children's Hospital, Cincinnati

48109

University of Michigan, Ann Arbor

52242

University of Iowa, Iowa City

55455

University of Minnesota, School of Medicine, Minnesota City

60153

Loyola University Medical Center, Maywood

60611

Lurie Children's Hospital, Chicago

60637

University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

64108

Children's Mercy Hospital, Kansas City

66160

University of Kansas, Kansas City

73104

University of Oklahoma, Oklahoma City

77030

Baylor College of Medicine, Houston

Texas Children's Hospital, Houston

The University of Texas MD Anderson Cancer Center, Houston

80045

Children's Hospital Colorado, Aurora

84108

University of Utah, Salt Lake City

85054

Mayo Clinic-Arizona, Phoenix

91010

City of Hope, Duarte

92121

Ansun Biopharma, Inc, San Diego

92868

Children's Hospital of Orange County, Orange

94305

Stanford University Medical Center, Palo Alto

95817

UC Davis, Sacramento

98105

Seattle Children's Hospital, Seattle

98195

University of Washington Medical Center, Seattle

02115

Beth Israel Deaconess Medical Center, Boston

Brigham & Women's Hospital, Boston

07601

Hackensack University Medical Center, Hackensack

11794-88183

Stonybrook, Stony Brook

98109-1024

Fred Hutchinson Cencer Research Center, Seattle

Sponsors
All Listed Sponsors
lead

Ansun Biopharma, Inc.

INDUSTRY

NCT01644877 - A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen | Biotech Hunter | Biotech Hunter